Topline pivotal data expected for zidesamtinib in TKI pre-treated ROS1-positive NSCLC population in the first half of 2025 in support of anticipated first NDA submission by mid-year 2025 Initiation of ALKAZAR Phase 3 randomized, controlled trial of neladalkib for front-line ALK-positive...
Read More Details
Finally We wish PressBee provided you with enough information of ( Nuvalent Outlines Recent Pipeline and Business Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2025 Financial Results )
Also on site :
- Smoke Signal? Motorcyclist Records Mysterious Black Ring Hovering In Sky Over Kansas (WATCH)
- Defiant Serbian leader sends message to EU from Red Square (VIDEO)
- Kylie Jenner's Dangerously Busty Display Is a 'Top Tier' Look